Search Results

Armenia Responds to Claims of Metsamor NPP Closure: Operating License Valid Until 2036

In response to Azerbaijani President Ilham Aliyev's claims that the Metsamor Nuclear Power Plant is outdated and could pose a potential threat to the region, Arman Yeghoyan, a lawmaker from Armenia's ruling Civil Contract party, stated that the operating lifetime of a nuclear power plant is not unilaterally determined by the governments of neighboring countries. Yeghoyan noted that every nuclear power plant has an established operating period, and the Metsamor NPP is currently authorized to operate for a maximum term extending to 2036, information that has long been public. He also stated that the Armenian side has announced it is studying options for building a new nuclear power plant...

2026-08-14

Azerbaijan Says It Can Supply Electricity to Armenia, Focus on Metsamor Nuclear Power Plant Decommissioning Replacement

Azerbaijani President Ilham Aliyev said on August 12 that Azerbaijan could supply electricity to Armenia. He also stated that Armenia cannot indefinitely extend the operating lifetime of the Metsamor Nuclear Power Plant. The Armenian government has not yet responded to this proposal, nor has it indicated whether it would consider importing electricity from Azerbaijan. As signs of easing relations between the two countries emerge, the possibility of cross-border transportation and energy infrastructure development is being revisited. Armenia has long relied on Russia and Iran for its energy security. Currently, the country is studying proposals from companies in the United States, Russia, China...

2026-08-13

China Bio-Pharma: Enters Cooperation Agreement with Stella Pharma on Boron Neutron Therapy Drug

China Bio-Pharma Holdings Limited announced on August 12 that the company, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd., and Japan's Stella Pharma Corporation signed a legally binding Master Cooperation Agreement on August 11, 2026, to jointly advance the development and commercialization of Steboronine in China. Steboronine is described in the announcement as the world's first approved boron neutron therapy drug, applied in Boron Neutron Capture Therapy (BNCT). Under the agreement, the cooperation between the two parties is divided into a development phase and a commercialization phase. During the development phase, the cooperation aims to leverage real-world data, real-world evidence, and real-world studies generated by the China Bio-Pharma Group to facilitate Stella Pharma in obtaining and maintaining, as soon as possible, marketing approval from China's National Medical Products Administration (NMPA) for Steboronine for the treatment of head and neck cancer; after Stella Pharma obtains marketing and manufacturing approval from the Japanese government for Steboronine for meningioma, the relevant China filings may also be extended to the meningioma indication.

2026-08-12

Curium Acquires Belgium's Abscint, Expanding HER2-Targeted Gallium-68 PET Oncology Radiopharmaceutical Diagnostics Pipeline

On August 10, 2026, radiopharmaceutical company Curium announced the completion of its acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company. The transaction grants Curium global development, manufacturing, and commercialization rights to ABS-011, further expanding its oncology PET radiopharmaceutical diagnostics portfolio. ABS-011 is an investigational gallium-68-labeled positron emission tomography (PET) radiopharmaceutical diagnostic tracer targeting human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in multiple cancers, including breast cancer and gastric cancer. Based on available information, ABS-011 is designed to enable whole-body quantitative imaging of HER2 expression, and following further clinical development and regulatory approval, has the potential to provide more comprehensive HER2 status information for patient characterization and clinical assessment.

2026-08-11

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

On August 9, 2026, Grand Pharmaceutical issued a voluntary announcement stating that its self-developed global innovative radionuclide drug conjugate GPN01530-2 has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of solid tumors. Previously, the product had already been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. GPN01530-2 is a small-molecule radionuclide drug conjugate (RDC) targeting fibroblast activation protein (FAP). Data shows that FAP is not expressed or is lowly expressed in normal tissues, but is highly expressed in tumor-associated fibroblasts within the tumor microenvironment of various cancers, and is considered a novel specific target in the field of tumor diagnosis and treatment...

2026-08-10

South Korea to Resume Actinium-225 Production Next Year to Ease Shortage of Raw Materials for Anti-Cancer Radiopharmaceuticals

South Korea's domestic production project for actinium-225 (Ac-225), a radioisotope used in next-generation cancer treatment, is expected to resume next year after being stalled for more than a year. Funding was secured in the first half of this year, and the Korea Institute of Radiological & Medical Sciences (KIRAMS) plans to complete facility construction and trial production before launching full-scale production in the second half of next year, aiming to alleviate the raw material shortage facing domestic clinical research and radiopharmaceutical development. KIRAMS is affiliated with the Ministry of Science and ICT. The institute received approval from the Nuclear Safety and Security Commission in May last year to produce Ac-225 using a cyclotron. The project first entered the review process in 2018 and took seven years to gain approval, with initial production originally planned by the end of last year. However, work on upgrading production facilities and procuring equipment was suspended after approximately 2 billion KRW in budget was not approved during parliamentary review.

2026-08-10

UAB startup LifeNuclear launches TheraGuide, a radiation safety guidance platform for radiopharmaceutical therapy

On August 7, LifeNuclear, a medical technology startup incubated by the University of Alabama at Birmingham (UAB), announced the launch of TheraGuide, a digital platform designed to help patients undergoing radiopharmaceutical cancer treatment understand and follow radiation safety guidance after discharge. Radiopharmaceutical therapy uses radioactive drugs to target cancer cells while minimizing damage to surrounding healthy tissue. As the therapy's applications expand, patients are typically required to read and follow complex written instructions after treatment, which can be difficult for some patients and caregivers to understand and execute. Dr. Remo George LifeNuclear was founded by UAB...

2026-08-08

China's First Homegrown Radiopharmaceutical Receives Dual FDA Breakthrough Therapy and Fast Track Designations

On August 6, Nuoyu Medical announced that the U.S. Food and Drug Administration (FDA) has officially granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to the company's independently developed 68Ga-NYM096. This marks the first product in China's original radiopharmaceutical field to receive FDA Breakthrough Therapy Designation, and the first to receive both FDA Breakthrough Therapy and Fast Track designations simultaneously, creating a milestone breakthrough in the radiopharmaceutical field. 68Ga-NYM096 is a small-molecule diagnostic radiopharmaceutical for renal cancer that specifically binds to CAIX, suitable for positron emission tomography (PET) imaging of suspected or confirmed metastatic clear cell renal cell carcinoma (c...

2026-08-08

Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences

Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...

2026-08-07

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

CGN Launches "Chunhe Plan" and Digital Science Popularization Platform "Nuclear Harmony Planet"

On August 7, at the 14th "8·7 Public Open Experience Day" of CGN, CGN released the "Chunhe Plan," a long-term mechanism for publicly recruiting science popularization "nuclear partners," and simultaneously launched the "Nuclear Harmony Planet" mini-program, the first digital science popularization platform in China's nuclear power industry. The Chunhe Plan aims to systematically expand the coverage scenarios of nuclear power science popularization and promote the accessibility of clean energy knowledge. Among its initiatives, villagers near nuclear power plants can become docents under the "Chunhe Dialect" program through training and assessment, earning compensation per service session; the "Chunhe Campus" program provides standardized training and certification for primary and secondary school teachers, equips them with dedicated teaching aids and course materials, and simultaneously opens up student study tour practice channels. On the same day, various CGN nuclear power bases and...

2026-08-07

Indonesia's BRIN Showcases Nuclear Technology Research Progress, Covering Radiopharmaceuticals and Food Irradiation Applications

The National Research and Innovation Agency (BRIN) of Indonesia recently showcased its nuclear technology research achievements at the Presidential Palace in Jakarta. BRIN Head Arief Satria stated that the relevant technologies fall within the scope of peaceful uses of nuclear energy, with applications extending beyond energy to also cover food and health sectors. In the health sector, BRIN is developing radiopharmaceuticals for nuclear medicine. These drugs contain radioactive substances and can be used for cancer diagnosis and treatment. Arief stated that radiopharmaceutical research and development is of great significance for cancer detection and therapy. In the food sector, BRIN applies nuclear technology to food preservation, with a focus on irradiation treatment of export fruits. Arief explained that some importing countries re...

2026-08-07

South Korea Advances First Domestic Commercial Production of Lu-177 Using Wolsong Heavy Water Reactors

Korea Hydro & Nuclear Power (KHNP) plans to use the heavy water reactors at the Wolsong Nuclear Power Plant to produce, for the first time domestically, the radioisotope lutetium-177 (Lu-177) for cancer treatment. Currently, South Korea relies entirely on imports for this material, which imposes cost pressures and supply instability on local radiopharmaceutical companies such as Cellbion and FutureChem. Industry experts generally believe that domestic production will help build a diversified supply chain and shorten transportation times. The primary goal of this plan is to achieve commercial production of Lu-177, with pilot production expected in 2028 and full-scale production commencing in 2031. Subsequently, KHNP will expand production to include cobalt...

2026-08-06

Zhang Yiming, Chairman of HTA: Tackling the "Last Mile" of Nuclear Pharmacy Network Delivery to Bring Domestic Radiopharmaceuticals to Patients in Western and County-Level Regions

On July 28, the 2026 Radiopharmaceutical Innovation and Development Conference was held in Taiyuan, Shanxi Province. Zhang Yiming, Party Committee Secretary and Chairman of HTA, told reporters that the company is restructuring its short half-life radiopharmaceutical delivery system through "regional layout + standardized logistics + grassroots empowerment," striving to ensure that cancer patients in western and county-level regions can access domestically produced radiopharmaceuticals within the drug's effective half-life window. Currently, multi-dimensional policy dividends are being continuously released, and China's radiopharmaceutical industry is entering a critical window of opportunity. Alpha nuclide drugs represent the future direction of therapeutic radiopharmaceuticals. Zhang Yiming introduced that HTA has already made early arrangements for drug research in this field, jointly conducting research on actinium-225 labeled...

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04